HC Wainwright & Co. Maintains Buy on Cadrenal Therapeutics, Lowers Price Target to $13
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Joseph Pantginis maintains Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and lowers the price target from $32 to $13.
HC Wainwright & Co. analyst Joseph Pantginis maintains Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and lowers the price target from $32 to $13.